HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor.
HCV Peptide (35-44) (0-100 μM) inhibits degranulation of the total NK cell population. HCV Peptide (35-44) increases cell surface expression of both HLA-C and HLA-E[1].
References:
[1]. Cheent KS, et, al. P91 Dual mechanism of NK cell inhibition by the HCV core 35–44 peptide. BMJ journals. 60(Sup 2).
















